Tizanidine Hydrochloride Capsule
Product Images NDC 72888-003

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 72888-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (2 mg 150 Capsules Bottle)

Label for tizanidine hydrochloride Capsules 2 mg by Advagen Pharma Limited with a package count of 150 capsules. The label states the active ingredient strength as 2 mg (equivalent to 2.29 mg tizanidine hydrochloride USP) and notes the product is Rx only. The label includes storage instructions, distributor and manufacturer information, barcode, and a warning about non-interchangeability with Zanaflex tablets.*

FDA Label Image

Principal Display Panel (4 mg 150 Capsule Bottle)

Label for Tizanidine Hydrochloride Capsules 4 mg by Advagen Pharma Limited. The label indicates 150 capsules per container, with NDC 72888-002-15. It includes storage instructions, a warning to keep medication out of reach of children, and distribution details. The label also notes the product is not interchangeable with tizanidine or Zanaflex tablets and provides manufacturing information for Rubicon Research Private Limited.*

FDA Label Image

Principal Display Panel (6 mg 150 Capsule Bottle)

Label for tizanidine hydrochloride 6 mg capsules, distributed by Advagen Pharma Limited and manufactured by Rubicon Research Private Limited. The label indicates each capsule contains 6.87 mg tizanidine hydrochloride, equivalent to 6 mg tizanidine base, and the package contains 150 capsules. It includes storage instructions, a child-resistant closure warning, a barcode, and a note that this product is not interchangeable with tizanidine tablets or Zanaflex tablets.*

FDA Label Image

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)

A pharmacokinetic profile chart showing plasma concentration (ng/mL) of tizanidine over time (hours) after dosing. Four curves represent 2 mg and 4 mg tizanidine tablets and capsules, both with and without food, mapping concentration changes up to 24 hours post-dose.*

FDA Label Image

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)

A line graph demonstrating improvement in Ashworth Score over time post-dose in hours. It compares three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo, showing score improvement from 0 to 6 hours after dosing with error bars indicating variability.*

FDA Label Image

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)

A line chart comparing improvement in Ashworth Score over three study time points (end of titration, end of maintenance, and endpoint) between tizanidine hydrochloride (mean dose 28.8 mg) and placebo groups. The vertical axis represents improvement scores, with data points plotted and error bars shown for each group at each time point.*

FDA Label Image

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)

Chemical structure of tizanidine hydrochloride, showing the molecular arrangement with chlorine, nitrogen, sulfur atoms, and the attached hydrochloride group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.